{"schema_version":"secwatch.filing_event.v1","accession":"0001396814-25-000060","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.158979+00:00","generated_at":"2026-05-22T03:43:59.780909+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pacira Q1 revenue $168.9M, net income $4.8M; EXPAREL exclusivity extended to 2039","bullets":["Total revenues $168.9M (+1% YoY); GAAP net income $4.8M ($0.10) vs $9.0M ($0.19) a year ago.","EXPAREL net sales $136.5M (+3% YoY) with 7% daily volume growth; ZILRETTA $23.3M (-10%).","Patent litigation settled with Fresenius Kabi; limited-volume entry starts at high single-digit % of U.S. volume, exclusivity to 2039.","Court ruling eliminates EXPAREL royalty obligation to RDF; future payments stopped, repayment sought.","Reiterates FY2025 guidance: revenue $725-765M, non-GAAP gross margin 76-78%."],"urls":{"canonical":"https://secwatch.observer/filing/0001396814-25-000060","json":"https://secwatch.observer/filing/0001396814-25-000060.json","markdown":"https://secwatch.observer/filing/0001396814-25-000060.md","text":"https://secwatch.observer/filing/0001396814-25-000060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000139681425000060/0001396814-25-000060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000139681425000060/pcrx-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T03:43:59.780909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}